Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12272-021-01331-9 http://scihub22266oqcxt.onion/10.1007/s12272-021-01331-9 34047940!8161353!34047940     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arch+Pharm+Res 2021 ; 44 (5): 499-513 Nephropedia Template TP {{tp|p=34047940|t=2021. COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development |pdf=|usr=}}{{34047940}} gab.com Text COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development JO: Arch Pharm Res http://www.kidney.de/pget.php?&tw=1&pmid=34047940 #FOAvip In 2019, an unprecedented disease named coronavirus disease 2019 (COVID-19) emerged and spread across the globe. Although the rapid transmission of COVID-19 has resulted in thousands of deaths and severe lung damage, conclusive treatment is not available. However, three COVID-19 vaccines have been authorized, and two more will be approved soon, according to a World Health Organization report on December 12, 2020. Many COVID-19 patients show symptoms of acute lung injury that eventually leads to pulmonary fibrosis. Our aim in this article is to present the relationship between pulmonary fibrosis and COVID-19, with a focus on angiotensin converting enzyme-2. We also evaluate the radiological imaging methods computed tomography (CT) and chest X-ray (CXR) for visualization of patient lung condition. Moreover, we review possible therapeutics for COVID-19 using four categories: treatments related and unrelated to lung disease and treatments that have and have not entered clinical trials. Although many treatments have started clinical trials, they have some drawbacks, such as short-term and small-group testing, that need to be addressed as soon as possible. Twit Text FOAVip COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development ????Arch Pharm Res http://www.kidney.de/pget.php?&tw=1&pmid=34047940 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34047940 #FOAvip English Wikipedia <ref>{{Cite pmid|34047940}}</ref> COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development #MMPMID34047940 Yim J; Lim HH; Kwon Y Arch Pharm Res 2021[May]; 44 (5): 499-513 PMID34047940show ga In 2019, an unprecedented disease named coronavirus disease 2019 (COVID-19) emerged and spread across the globe. Although the rapid transmission of COVID-19 has resulted in thousands of deaths and severe lung damage, conclusive treatment is not available. However, three COVID-19 vaccines have been authorized, and two more will be approved soon, according to a World Health Organization report on December 12, 2020. Many COVID-19 patients show symptoms of acute lung injury that eventually leads to pulmonary fibrosis. Our aim in this article is to present the relationship between pulmonary fibrosis and COVID-19, with a focus on angiotensin converting enzyme-2. We also evaluate the radiological imaging methods computed tomography (CT) and chest X-ray (CXR) for visualization of patient lung condition. Moreover, we review possible therapeutics for COVID-19 using four categories: treatments related and unrelated to lung disease and treatments that have and have not entered clinical trials. Although many treatments have started clinical trials, they have some drawbacks, such as short-term and small-group testing, that need to be addressed as soon as possible. |*COVID-19 Drug Treatment[MESH] |*Drug Development[MESH] |*Drug Repositioning[MESH] |Angiotensin-Converting Enzyme 2/metabolism[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/complications/diagnostic imaging[MESH] |Humans[MESH] |Pulmonary Fibrosis/diagnostic imaging/*drug therapy/etiology[MESH] |Radiography, Thoracic[MESH]COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repu(epmc).pdf DeepDyve Pubget Overpricing